WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > Elemental Impurity Analysis in Pharmaceuticals and Implementation of ICH Q3D
I'm For Real
Enter your details once to access all our information and resources
Starting a century ago, CSL Behring made a promise to save lives and protect the health of people stricken with a range of serious and chronic medical conditions. Today that same promise has never been stronger.
whitePaper | July 1, 2023
As its title implies, Annex 1 is the European guidance document for good manufacturing practices of medicinal products. As such, it serves as the road map for sterile drug manufacturers to follow in order to arrive at the pathway to the highest level of sterility, assuring that their medicinal drug products deploy operational best practices, are certifiable, and regulatorily safe.
whitePaper | March 28, 2023
About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.
whitePaper | December 19, 2019
Welcome to European Pharmaceutical Review’s Application Notes & Whitepapers Supplement 2019. This year’s topics range from analytical techniques for bioprocess investigation, host cell protein analysis and Raman imaging to advice on outsourcing services for product characterisation.
whitePaper | March 27, 2023
European countries have been experiencing medicine shortages due to disruptions in the supply chain. Reshoring the productions of active pharmaceutical ingredients (APIs) is considered as an approach to secure the supply.
whitePaper | November 18, 2022
Small molecule drug development has changed substantially in recent years. With the heightened focus on molecularly targeted therapies, small molecule active pharmaceutical ingredients (APIs).
whitePaper | November 8, 2022
The Asia-Pacific region has emerged as a clinical trial hub due to the ease of regulatory compliance, low trial costs, rising patient population, and the availability of top clinical institutions.
Conference
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE